Literature DB >> 19062016

Osteoprotegerin as an independent marker of subclinical atherosclerosis in osteoporotic postmenopausal women.

M Shargorodsky1, M Boaz, A Luckish, Z Matas, D Gavish, M Mashavi.   

Abstract

Osteoprotegerin (OPG) appears to represent the molecular link between bone resorption and vascular calcification, and may help to explain the high prevalence of atherosclerosis and osteoporosis in postmenopausal women. We investigated a possible association between serum OPG levels and arterial stiffness in postmenopausal women with osteoporosis. 70 postmenopausal women with osteoporosis and cardiovascular risk factors but without coronary artery disease were evaluated for metabolic, inflammatory parameters and serum OPG levels. Pulse wave velocity (PWV) and augmentation index (AIx) were performed as a simple noninvasive recording of the two artery sites pressure waveform using SphygmoCor (version 7.1, AtCor Medical, Sydney, Australia). Serum OPG levels were significantly, positively associated with AIx (r=0.39, p=0.003) and with PWV (r=0.81, p<0.0001). No association between OPG levels and hemodynamic variables or measures of glucose metabolism was observed. Among inflammatory markers, OPG was significantly, positively associated with fibrinogen (r=0.323, p=0.015). In a multiple linear regression analysis, OPG was independent predictor of PWV (standardized beta=0.75, p<0.0001) and AIx (standardized beta=0.41, p=0.01). Serum OPG is potentially an independent predictor of early vascular adverse changes in osteoporotic postmenopausal women.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19062016     DOI: 10.1016/j.atherosclerosis.2008.10.024

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  12 in total

1.  Serum osteoprotegerin: bone or cardiovascular marker in Type 2 diabetes males?

Authors:  P Rozas Moreno; R Reyes García; A García-Martín; M Varsavsky; J A García-Salcedo; M Muñoz-Torres
Journal:  J Endocrinol Invest       Date:  2012-02-28       Impact factor: 4.256

Review 2.  Osteoporosis--a risk factor for cardiovascular disease?

Authors:  Christos E Lampropoulos; Ioanna Papaioannou; David P D'Cruz
Journal:  Nat Rev Rheumatol       Date:  2012-08-14       Impact factor: 20.543

3.  Physical exercise, fitness and dietary pattern and their relationship with circadian blood pressure pattern, augmentation index and endothelial dysfunction biological markers: EVIDENT study protocol.

Authors:  Luis García-Ortiz; José I Recio-Rodríguez; Carlos Martín-Cantera; Alfredo Cabrejas-Sánchez; Amparo Gómez-Arranz; Natividad González-Viejo; Eguskiñe Iturregui-San Nicolás; Maria C Patino-Alonso; Manuel A Gómez-Marcos
Journal:  BMC Public Health       Date:  2010-05-06       Impact factor: 3.295

4.  Serum Osteoprotegerin and Carotid Intima-Media Thickness Are Related to High Arterial Stiffness in Heart Failure with Reduced Ejection Fraction.

Authors:  Lajos Fehérvári; Attila Frigy; Lóránd Kocsis; István Adorján Szabó; Timea Magdolna Szabo; Melinda Urkon; Zita Jakó; Előd Ernő Nagy
Journal:  Diagnostics (Basel)       Date:  2021-04-24

Review 5.  The mechanism of vascular calcification - a systematic review.

Authors:  Wojciech Karwowski; Beata Naumnik; Marek Szczepański; Michal Myśliwiec
Journal:  Med Sci Monit       Date:  2012-01

Review 6.  Vascular calcification and renal bone disorders.

Authors:  Kuo-Cheng Lu; Chia-Chao Wu; Jen-Fen Yen; Wen-Chih Liu
Journal:  ScientificWorldJournal       Date:  2014-07-17

7.  Serum osteoprotegerin levels associated with the aortic augmentation index in renal transplant recipients.

Authors:  Bang-Gee Hsu; Chung-Jen Lee; Yen-Cheng Chen; Guan-Jin Ho; Teng-Yi Lin; Ming-Che Lee
Journal:  Ci Ji Yi Xue Za Zhi       Date:  2016-02-09

8.  Relationship Between Serum Total Testosterone Concentration and Augmentation Index at Radial Artery in Japanese Postmenopausal Patients.

Authors:  Takashi Hitsumoto
Journal:  J Clin Med Res       Date:  2017-09-01

9.  Osteoprotegerin as a marker of atherosclerosis in diabetic patients.

Authors:  Areti Augoulea; Nikolaos Vrachnis; Irene Lambrinoudaki; Konstantinos Dafopoulos; Zoe Iliodromiti; Angelos Daniilidis; Michail Varras; Andreas Alexandrou; Efthymios Deligeoroglou; George Creatsas
Journal:  Int J Endocrinol       Date:  2013-01-17       Impact factor: 3.257

10.  Therapeutic implications of osteoprotegerin.

Authors:  Sofia Fili; Maria Karalaki; Bernhard Schaller
Journal:  Cancer Cell Int       Date:  2009-09-12       Impact factor: 5.722

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.